The mechanism of action includes antigenic modulation of the CD3/TCR complex with subsequent opsonisation and removal of circulating T cells; other mechanisms are proposed. Cytokine release associated with an acute phase reaction occurs after the first doses of muromonab CD3. This is manifest as ...
It is indicated in acute allograft rejection treatment and its side-effects are strongly linked with its mechanism of action. ORT/OKT3 is an Ig2a immunoglobulin produced by hybridoma technique that recognizes, binds and blocks the CD3 complex of the T-cell receptor. Two types of side-effects ...